HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tsutomu Takeuchi Selected Research

Methotrexate (Mexate)

11/2022Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.
4/2022Efficacy and safety of abatacept in biologic-naïve patients with active rheumatoid arthritis by background methotrexate dose: post hoc analysis of a randomized, placebo-controlled, phase 4 study.
2/2022Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
2/2022Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
1/2022Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study.
6/2021Steroid-Sparing Effect of Tocilizumab and Methotrexate in Patients with Polymyalgia Rheumatica: A Retrospective Cohort Study.
5/2021Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study.
1/2021Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
1/2021A phase 2a, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral gonadotropin-releasing hormone antagonist, ASP1707, in postmenopausal female patients with rheumatoid arthritis taking methotrexate.
10/2020ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tsutomu Takeuchi Research Topics

Disease

263Rheumatoid Arthritis
11/2022 - 06/2003
46Infections
07/2022 - 08/2002
22Immunoglobulin G4-Related Disease
07/2022 - 01/2012
22Systemic Lupus Erythematosus (Libman-Sacks Disease)
05/2022 - 09/2003
21Interstitial Lung Diseases (Interstitial Lung Disease)
01/2022 - 09/2005
17Herpes Zoster
07/2022 - 01/2016
15Rheumatic Diseases (Rheumatism)
04/2022 - 01/2007
14Autoimmune Diseases (Autoimmune Disease)
01/2022 - 08/2005
13Inflammation (Inflammations)
05/2022 - 08/2003
11Necrosis
01/2021 - 07/2011
10Neoplasms (Cancer)
05/2022 - 12/2002
9Lupus Nephritis
07/2022 - 01/2007
9Arthritis (Polyarthritis)
01/2022 - 01/2006
9Adult-Onset Still's Disease
01/2022 - 03/2012
9Fever (Fevers)
05/2021 - 09/2005
9Pain (Aches)
01/2021 - 05/2012
9Cysts
06/2012 - 09/2002
8Pneumonia (Pneumonitis)
03/2021 - 01/2007
7Opportunistic Infections (Opportunistic Infection)
01/2021 - 01/2005
7Drug-Related Side Effects and Adverse Reactions
05/2020 - 11/2010
7Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia)
11/2012 - 01/2007
6Lymphoproliferative Disorders (Lymphoproliferative Disorder)
01/2022 - 02/2007
6Systemic Scleroderma (Systemic Sclerosis)
10/2021 - 01/2007
6Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis)
10/2021 - 01/2015
5Vasculitis (Vasculitides)
07/2022 - 01/2021
5Connective Tissue Diseases (Connective Tissue Disease)
11/2021 - 03/2013
5Disease Progression
11/2021 - 12/2017
5Myositis (Idiopathic Inflammatory Myopathies)
01/2021 - 09/2005
5Nasopharyngitis
01/2019 - 06/2016
5Arthralgia (Joint Pain)
11/2018 - 07/2011
5Amebiasis (Amoebiasis)
02/2006 - 08/2003
4Psoriatic Arthritis
07/2022 - 08/2017
4Dermatomyositis (Dermatopolymyositis)
01/2022 - 09/2005
4Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
11/2021 - 01/2020
4Juvenile Arthritis (Juvenile Idiopathic Arthritis)
10/2021 - 08/2017
4Mixed Connective Tissue Disease (MCTD)
01/2021 - 10/2012
4Joint Diseases (Joint Disease)
12/2017 - 10/2013
4Communicable Diseases (Infectious Diseases)
01/2016 - 10/2003
4Lung Diseases (Lung Disease)
10/2015 - 11/2012

Drug/Important Bio-Agent (IBA)

81Methotrexate (Mexate)FDA LinkGeneric
11/2022 - 12/2004
44Biological ProductsIBA
05/2022 - 01/2005
43tocilizumab (atlizumab)FDA Link
10/2022 - 09/2007
34Infliximab (Remicade)FDA Link
07/2022 - 01/2005
31Antirheumatic Agents (DMARD)IBA
11/2021 - 01/2006
28GlucocorticoidsIBA
01/2022 - 02/2003
26Adalimumab (Humira)FDA Link
02/2022 - 06/2012
24Interleukin-6 (Interleukin 6)IBA
01/2022 - 06/2004
24Monoclonal AntibodiesIBA
07/2021 - 10/2003
21Immunoglobulin G (IgG)IBA
07/2022 - 01/2005
21Biomarkers (Surrogate Marker)IBA
09/2021 - 01/2009
21Etanercept (Enbrel)FDA Link
03/2021 - 12/2002
20Abatacept (Orencia)FDA Link
04/2022 - 03/2013
18CytokinesIBA
01/2022 - 02/2003
17Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2022 - 01/2005
16Pharmaceutical PreparationsIBA
02/2022 - 10/2002
15baricitinibIBA
01/2022 - 01/2017
14C-Reactive ProteinIBA
05/2021 - 01/2008
13Janus Kinase InhibitorsIBA
07/2022 - 01/2016
12InterleukinsIBA
01/2022 - 11/2013
12Prednisolone (Predate)FDA LinkGeneric
01/2022 - 09/2005
12AutoantibodiesIBA
05/2021 - 01/2011
11peficitinibIBA
07/2022 - 06/2016
11AntibodiesIBA
01/2021 - 02/2003
11Certolizumab PegolFDA Link
03/2020 - 07/2014
11Adrenal Cortex Hormones (Corticosteroids)IBA
09/2019 - 09/2005
11EnzymesIBA
11/2018 - 01/2004
10Tacrolimus (Prograf)FDA LinkGeneric
11/2021 - 02/2009
10Tumor Necrosis Factor InhibitorsIBA
07/2021 - 07/2011
9Rituximab (Mabthera)FDA Link
01/2022 - 01/2007
9Proteins (Proteins, Gene)FDA Link
05/2021 - 03/2002
8tofacitinibIBA
10/2022 - 07/2015
8Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
11/2021 - 01/2011
7GLPG0634IBA
04/2022 - 01/2019
7DenosumabFDA Link
11/2021 - 06/2016
7sirukumabIBA
01/2021 - 06/2017
7golimumabFDA Link
01/2020 - 06/2012
7Interleukin-6 Receptors (Interleukin 6 Receptor)IBA
01/2020 - 01/2009
6Immunosuppressive Agents (Immunosuppressants)IBA
11/2021 - 06/2005
6upadacitinibIBA
06/2021 - 01/2020
6AntigensIBA
01/2021 - 03/2004
6Janus KinasesIBA
10/2020 - 06/2017
6Messenger RNA (mRNA)IBA
06/2012 - 09/2003
5omega-Chloroacetophenone (Mace)IBA
04/2022 - 01/2019
5SteroidsIBA
01/2022 - 05/2015
5Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2021 - 09/2005
5Leflunomide (Arava)FDA LinkGeneric
01/2020 - 01/2008
4Biosimilar PharmaceuticalsIBA
07/2022 - 06/2017
4Interleukin-4 (Interleukin 4)IBA
01/2022 - 09/2010
4Cyclosporine (Ciclosporin)FDA LinkGeneric
11/2021 - 09/2005
4ametantrone (HAQ)IBA
01/2021 - 01/2009
4DNA (Deoxyribonucleic Acid)IBA
01/2020 - 06/2003
4Sulfasalazine (Azulfidine)FDA LinkGeneric
01/2020 - 10/2013
4beta-cyclodextrin tetradecasulfate (CTDS)IBA
01/2020 - 10/2012
4Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA
04/2018 - 07/2011
4zeta chain antigen T cell receptor (TCR zeta chain)IBA
08/2005 - 09/2003
3CT-P13IBA
07/2022 - 01/2015
3Anti-Citrullinated Protein AntibodiesIBA
04/2022 - 06/2014

Therapy/Procedure

83Therapeutics
11/2022 - 08/2002
4Aftercare (After-Treatment)
05/2018 - 01/2011
4Biological Therapy
05/2015 - 11/2010